Find 47 companies with promising cash flow potential yet trading below their fair value.
To own Waters, you need to believe in its role as a core provider of analytical workflow solutions while it manages integration, margin, and end‑market pressures. The recent Q1 beat against expectations supports the near term catalyst of renewed confidence in execution, but does not materially reduce the key risk around integrating BD’s Biosciences and Diagnostic Solutions businesses and delivering the sizeable cost and revenue synergies that many forecasts rely on.
The most relevant recent development here is Waters’ Q1 2026 earnings, where revenue reached US$1,267 million, ahead of guidance, but with a reported net loss driven by large one off items. That mix of stronger demand signals and compressed profitability sits right at the intersection of the integration and margin risks, and will likely shape how investors weigh the upside from BD’s assets against the execution challenges in the coming quarters.
Yet beneath the upbeat Q1 reaction, one risk investors should be aware of is how much now hinges on successful integration of BD’s businesses and...
Read the full narrative on Waters (it's free!)
Waters’ narrative projects $7.5 billion revenue and $1.4 billion earnings by 2029.
Uncover how Waters' forecasts yield a $393.14 fair value, a 15% upside to its current price.
Some of the most optimistic analysts were already assuming Waters could reach about US$8.3 billion in revenue and US$1.4 billion in earnings by 2029, so Q1’s surprise leaves open the question of whether that upbeat view or the more cautious concerns about overreliance on core technologies and digital gaps will end up closer to how things actually unfold.
Explore 3 other fair value estimates on Waters - why the stock might be worth just $393.14!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Contact Us
Contact Number :+852 3852 8500
English